Navigation Links
Neogen Reports First Quarter Revenue and Net Income Increases
Date:9/27/2011

LANSING, Mich., Sept. 27, 2011 /PRNewswire/ -- Neogen Corporation (Nasdaq: NEOG) announced today that its revenues for the first quarter of FY 2012, which ended Aug. 31, increased 6.5% to $45,697,000, from the previous year's first quarter revenues of $42,923,000. The current year's revenue increase is almost entirely comprised of products available in the prior year's first quarter.

First quarter net income increased 3.1% from the prior year to $6,004,000, or $0.25 per share. This compares to net income of $5,824,000 in the first quarter of FY 2011, also $0.25 per share. The first quarter revenues and net income represent quarterly records for the 29-year-old company.

"In the first quarter we continued our remarkable quarter-to-quarter success in consistent growth in sales and profits, while at the same time implementing our plan to ensure long-term growth," said James Herbert, Neogen's chief executive officer and chairman. "I'm very proud of our management team and employee group, who have kept our strong quarter-to-quarter growth going for more than 20 years."

The quarter marked the 74th consecutive profitable quarter from operations for the company, and was the 78th of the past 83 quarters when Neogen reported revenue increases as compared with the previous year — including the last 26 consecutive quarters.

"We are pleased to report yet another solid quarter, in spite of a difficult comparison with our previous fiscal year's first quarter. Last year at this time we reported a first quarter revenue increase of 33% that was bolstered by a significant spike in sales of two test kits primarily resulting from unusual weather conditions," said Lon Bohannon, Neogen's president and chief operating officer. "During the first quarter we were also able to move forward with some infrastructure improvements intended to accelerate future growth, including com
'/>"/>

SOURCE Neogen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neogen Launches Fully Quantitative Lateral Flow Test for Aflatoxin
2. Neogen Reports 30% Increase in Net Income
3. Neogen Corporation Announces Year-End Results Conference Call
4. Neogen Acquires VeroMara from GlycoMar Ltd.
5. William T. Boehm Joins Neogens Board of Directors
6. Neogen Reports 27% Increase in Quarterly Net Income
7. Neogens Rapid Test for Salmonella enteritidis Receives FDA Approval
8. Neogen Names Quinlan as CFO
9. Neogen Reports 33% Increase in Net Income
10. Neogen Corporation Announces 2nd Quarter Results Conference Call
11. Neogens Rapid Test for Salmonella enteritidis Receives AOAC Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: ... and commercializing innovative therapies addressing major unmet medical ... received the Notice of Allowance from the United ... self-delivering RNAi compounds (sd-rxRNA®), for the treatment of ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental products, has ... arch impressions on its dental blog. , Titled ... serves up a list of tips to help dentists best ... David Little as he crafts a porcelain crown using Kerr’s ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in Altadena ... ideas for 2014 in production and sales of interactive ... high-quality, low-cost, DRM-free ebooks and to use the sales ... first major development will be bookstore sales in local ...
Breaking Biology Technology:RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... ULURU Inc. (Amex:,ULU) today announced that it ... Food and Drug Administration (FDA) for Altrazeal(TM) Silver., ... have shown that,superior healing rates in numerous porcine ... dressings. Additionally, in toxicology and,in vitro bacteria inhibition ...
... (DIA) will host two co-located conferences from October 23-24 ... ... Horsham, PA (PRWEB) September 30, 2008 -- ... co-located conferences from October 23-24 in Washington DC. ...
... 30 Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTA: CTIC) ... on October 3, 2008. The investor day will provide ... regulatory milestones,for the Company. Additionally, Alessandro Gianni, M.D., Director ... University of Milan,who has authored over 300 publications will ...
Cached Biology Technology:ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver 2ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver 3DIA Co-located Conference to Examine Outsourcing and Project Management Best Practices 2Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008 2
(Date:4/18/2014)... survey of emergency contraceptive pills in Peru found ... either of substandard quality or falsified. Many pills ... the wrong active ingredient. One batch had no ... the fake drugs, researchers at the Georgia Institute ... spectrometry to quickly assess suspected counterfeit drugs and ...
(Date:4/18/2014)... sprout as soon as they,re planted may be good news ... careful. In the wild, a plant whose seeds sprouted at ... More than just an insurance policy against late frosts or ... long-term advantages too: Plants whose seeds put off sprouting ... finds in a team of researchers working at the National ...
(Date:4/17/2014)... Respiratory syncytial virus (RSV) is a leading cause ... in very young and elderly populations. Despite great ... cells through the fusion protein RSV F, which ... that prevent bundle formation limit RSV infection in ... degradation. In this issue of the Journal ...
Breaking Biology News(10 mins):Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Plants with dormant seeds give rise to more species 2JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6
... (SSB) and Adolf Kühner AG ,- Prototype of orbital ... Mai 2009 / b3c newswire / – ExcellGene ... biopharmaceutical industry, expands its product offering with the introduction ... rely on orbital shaking principles for mixing compared ...
... a patient,s healthy tissue as well as eradicating the ... especially invasive and often causing nasty side effects. ... more precise and accurate treatment for cancerous tumours by ... Real-time image-guided radiotherapy, combining radiation treatment with non-invasive MR ...
... Medical College of Georgia nurse researcher is among the first ... funding through the American Recovery and Reinvestment Act of 2009. ... jobs and the research of African-Americans in the Augusta community ... seeks to create or save more than 3.5 million jobs ...
Cached Biology News:ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor 2ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor 3MCG researcher among first to receive NIH stimulus funding 2
Troponin I (22B11)...
Microlite 1+ 1x12 Strip assembled, flat bottom; the ideal vessel for low signal luminescent reactions, offering medium binding with enhanced dynamic range, extra high reflectivity and minimal cross t...
Immulon 4 HBX 1x12 Strip, flat bottom; high binding extra surface with special resin and irradiation, offers maximum protein uptake....
... and pressurized syringe holder for any researcher who ... rate Microinjecting Fine microliter delivery ... to any new or existing perfusion rig - ... Connect to house air or a compressor (30 ...
Biology Products: